Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway

Figure 3

Alisertib enhances the antiproliferative activity of lenvatinib in HCC cells by blocking cell cycle progression and increasing apoptosis. (a) HepG2 and Hep3B cells were treated with lenvatinib, alisertib, or both for 48 hr. Flow cytometric analysis was then conducted to evaluate the cell cycle, and statistical analysis was performed. (b) HepG2 and Hep3B cells were treated with lenvatinib, alisertib, or both for 48 hr. Immunofluorescent staining of the spindles in cells used an antibody against α-tubulin (depicted in red). DNA was counterstained with DAPI (depicted in blue).

(a)

(b)